



PRESS RELEASE

Avesthagen - Kemwell Manufacturing Alliance for Biosimilars

Bangalore, May 10, 2011: Avesthagen Limited and Kemwell Biopharma Pvt Ltd signed a Memorandum of Understanding (MoU) that will enable Avesthagen to leverage Kemwell's biopharmaceutical manufacturing expertise for large scale manufacture of biosimilars. Avesthagen has a portfolio of eight biosimilars under various phases of development in the areas of autoimmune diseases, cancers, anemia, and cardiovascular disorders.

Kemwell will perform technology transfer, process improvement, scale-up and manufacturing of pre-clinical, clinical and commercial material of Avesthagen biosimilars.

Kemwell's new 15,000 sq. mt. Greenfield state-of-the-art facility in Bangalore includes process development labs, a cGMP facility with cell culture capacity of 2 x 2000 liters for drug substance manufacturing, and a cGMP drug product manufacturing facility with vial filling, lyophilization and pre-filled syringes capabilities that would be used for Avesthagen.

Biosimilars are one of the most keenly watched group of pharmaceuticals that are seen as a panacea for the lack of reasonably priced medicines in the developing and developed economies. Many blockbuster and high-priced biologics are to go off-patent in the next decade and biosimilar manufacturers are expected to reap the benefits.

Dr. Viloo Morawala-Patell, founder and Chairperson, Avesthagen stated, "Kemwell is well placed to accelerate Avesthagen's projects to get its Biosimilars to the global markets. Given Kemwell's global capabilities in terms of capacities, experience and expertise, Avesthagen has found a partner that is globally recognized to consistently deliver superior quality product in a timely manner. This enables Avesthagen to bring its products a step closer to the market."

Mr. Anurag Bagaria, CMD, Kemwell stated, "Over the last 30 years, Kemwell has always placed emphasis on delivering quality products on time and on a consistent basis. We are excited to begin work for Avesthagen from our new biologics facility and are confident of extending our record of high customer service to this new foray."

About Avesthagen Limited:

Avesthagen is India's leading integrated systems biology platform company that focuses on achieving convergence of food, pharma and population genetics leading to predictive preventive and personalized healthcare.

Avesthagen partners include multiple top 10 global companies in each of its fields of research. Since its inception Avesthagen has grown into one of India's leading healthcare biotech companies. In addition to its agri-biotechnologies product pipeline it has developed clinically validated botanical bioActives and a strong pipeline of bio-similars. www.avesthagen.com

Contact: anilram@avesthagen.com

About Kemwell Biopharma Pvt Ltd:

Bangalore-based Kemwell Biopharma Pvt. Ltd. (www.kemwellbiopharma.com) is a leading provider of formulations contract manufacturing and development services for multinational pharmaceutical companies for 30 years. From facilities in India and Sweden, Kemwell manufactures tablets, capsules, liquid orals, external drops, ointments, gels and creams. Kemwell's customers include 5 of the top 10 pharmaceutical companies in the world, manufacturing 4 of the top 10 brands in India. Kemwell's Pharmaceutical Development Unit provides services in clinical manufacturing and packaging, formulation and analytical development, stability studies, regulatory documentation etc. With a 100% commitment to pure play contract manufacturing, Kemwell has no branded products of its own in the market, thereby avoiding any conflict of interests with its customers. Kemwell has recently built a new state-of-the-art biologics manufacturing facility in Bangalore to offer process development and GMP manufacturing services for drug substance and drug product.